Articles

Insights on genome engineering, applications, and the science behind TIDE.

September 22, 20265 min read

The real cost of proving the safety of a gene-edited clone

Gene-edited iPSC therapies carry a regulatory price far beyond the lab: qualified sequencing assays, CDMO margins, and 3–6 month off-target packages. Where that cost really comes from — and how a simple Sanger-based approach like TIDE shortens the path from candidate clone to IND.

July 26, 20264 min read

TIDE Genetics' business developer chooses science over buzzwords

Business developer Jawahar Kopparam explains what makes TIDE Genetics different in an era of buzzwords — helping users bring the latest therapeutics to market with a method that already meets regulatory requirements.

June 4, 20264 min read

Plant breeders need more than new EU regulations to master CRISPR-based gene editing

With the EU expected to implement a new regulatory framework for new genomic techniques by 2027, plant breeders may soon get access to CRISPR tools that have transformed human therapeutics for years. But access alone is not enough — TIDE Genetics is working to bridge the plant-breeding and gene-editing communities.

May 21, 20265 min read

Gene editing analysis, simplified: a day at TIDE Genetics

How TIDE turns a standard Sanger sequencing trace into a quantified CRISPR indel spectrum—plus a look inside the TIDE Genetics lab in Amsterdam, where gene editing analysis is kept simple, accurate, and ready for regulated environments.

May 6, 20264 min read

How TIDE identifies genetic variants beyond CRISPR-induced indels

Researchers at the Institute for Research in Biomedicine Bellinzona used TIDER to resolve triplet-repeat expansions and contractions in Huntington's disease models, demonstrating how TIDE-based analyses extend well beyond CRISPR-induced indels.

April 22, 20265 min read

The TIDE shaping the CRISPR community in Copenhagen

Our CSO Lorenzo Bombardelli attended the CRISPR Medicine Conference in Copenhagen, where 500 attendees coordinated efforts to advance gene editing from the bench to the patient.

April 7, 20264 min read

TIDE Genetics Launches a New Platform for Gene Editing Analysis

For over a decade, TIDE has been the go-to tool for quick, accessible gene editing analyses. But as gene editing advances and moves toward the clinic, a standalone tool is no longer enough.

March 24, 20266 min read

CRISPR-based CASGEVY therapy uses TIDE

The first-ever FDA-approved CRISPR therapy doesn't use next-generation sequencing (NGS) to validate its potency assay. It uses TIDE, and there's a good reason why.